TREATMENT OF OPTIC ATROPHY

An isolated or purified antisense oligomer for modulating mRNA translation of the OPAL gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.

Saved in:
Bibliographic Details
Main Authors RICE, Kim, CHEN, Fred, GRAINOK, Janya, UTAMA, Sasiwimon, PITOUT, Ianthe
Format Patent
LanguageEnglish
French
German
Published 09.08.2023
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:An isolated or purified antisense oligomer for modulating mRNA translation of the OPAL gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.
Bibliography:Application Number: EP20210873742